View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Keynote Fireside Chat: How Juno Therapeutics Went from 30 to 300

  • September 4, 2016

  • Mark Frohlich, EVP of Portfolio Strategy, Juno Therapeutics sits down with investor, Mark Simon, Torreya Partners to talk about the progress Juno made as a small biotech company comprised of 30 people, now over 300, and the challenges they faced along the way including:

    – Decision making with 30 people versus 300
    – Leveraging outside resources as a small and emerging R&D company
    – When moving into phase II or phase III, understanding how that affects your budget
    – Determining when to explore a new disease area

    For more information on this session and the entire program, please visit CMO and R&D West Agenda.


    Mark Frohlich, MD
    EVP of Portfolio Strategy, Juno Therapeutics


    Mark Simon, MBA
    Partner, Torreya Partners